Characterizing Baclofen Withdrawal: A National Survey of Physician Experience - 13/08/21
, Linda E. Krach, MD b, c, Lisa D. Coles, PhD b, John Schrogie, MD d, James C. Cloyd, PharmD b, Robert L. Kriel, MD bAbstract |
Objective |
We studied physicians’ opinions and experiences concerning clinical concerns, perceived severity, occurrence, and management of baclofen withdrawal due to abrupt discontinuation.
Methods |
A nationwide 26-question electronic survey was distributed via e-mail to physicians (N = 952) representing varying specialties who manage spasticity with baclofen. A total of 110 physicians provided responses to the survey (response rate = 11.6%). Results were evaluated using descriptive statistics.
Results |
Withdrawal from both oral and intrathecal (IT) baclofen was recognized as a significant concern and was observed by most respondents. However, approximately 75% and 35% of respondents or their clinic sites lack established management protocols for managing anticipated interruption of oral or IT baclofen, respectively.
Conclusions |
These findings highlight the need for further research on and the development of guidelines for the prevention and treatment of baclofen withdrawal. The results of this survey, along with a systematic literature review and multidisciplinary stakeholder input, may be helpful in establishing guidelines for the treatment and prevention of baclofen withdrawal.
Le texte complet de cet article est disponible en PDF.Keywords : Baclofen, Muscle spasticity, Survey, Baclofen administration & dosage, Baclofen adverse effects, Muscle spasticity/drug therapy, Substance withdrawal syndrome/therapy, Muscle relaxants
Plan
| The results of this investigation have been presented in part at annual meetings of the American Congress of Rehabilitation Medicine in Atlanta, GA, 2017 and the Association of Academic Physiatry in San Juan, Puerto Rico, 2019. |
|
| This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. |
|
| There was no funding for this study. |
|
| Author Disclosures: Drs Coles, Krach, Kriel, and Schmitz have nothing to disclose. Dr Schrogie reports personal fees from Allaysis, LLC. during the conduct of the study and outside of the submitted work. In addition, Dr Schrogie has a patent pending for IV baclofen. Dr Cloyd reports that the University of Minnesota has a licensing agreement with Allaysis LLC. related to the development of IV baclofen and will receive royalty payments should IV baclofen be commercialized. |
Vol 122
P. 106-109 - septembre 2021 Retour au numéro
Article précédent
- Moving Toward Understanding Autism: Visual-Motor Integration, Imitation, and Social Skill Development
- Daniel E. Lidstone, Stewart H. Mostofsky
- Threatening Blindness in a Child With Typical Hemolytic Uremic Syndrome
- Anaïs Corgier-Pattberg, Marie Beylerian, Stephanie Clave, Mathilde Cailliez, Benoit Testud, Beatrice Desnous
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?